Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks
CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...
Tag: hereditary angioedema
#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks
1. In this randomized controlled trial, oral sebetralstat provided faster times to the beginning of symptom relief than placebo in ...
Oral sebetralstat provides early symptom relief for hereditary angioedema attacks
1. In this randomized controlled trial, oral sebetralstat provided faster times to the beginning of symptom relief than placebo in ...
KLKB1 gene editing therapy reduces kallikrein levels in hereditary angioedema
1. In this randomized controlled trial, gene-editing therapy targeting the kallikrein B1 gene (KLKB1) led to a significant reduction in ...
Monthly prophylactic garadacimab significantly reduces hereditary angioedema attacks
1. Compared to placebo, monthly garadacimab significantly reduced the number of hereditary angioedema attacks per month. 2. Overall, garadacimab was ...
Sebetralstat improves symptom relief in acute hereditary angioedema attacks
1. An oral dose of sebetralstat increased the time to conventional treatment use and lead to faster symptom relief in ...
#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema
1. Patients with hereditary angioedema receiving donidalorsen showed reduced rates of angioedema attacks compared to patients receiving placebo treatment. 2. ...
Donidalorsen reduces attacks in patients with C1 inhibitor deficiency
1. Patients with hereditary angioedema receiving donidalorsen showed reduced rates of angioedema attacks compared to patients receiving placebo treatment. 2. ...
Garadacimab significantly reduces frequency of hereditary angioedema exacerbations
1. Garadacimab significantly reduced the number of monthly attacks in patients with hereditary angioedema compared to placebo. 2. No serious ...